- Report
- December 2021
- 40 Pages
Japan
From €1370EUR$1,500USD£1,172GBP
- Report
- December 2021
- 40 Pages
Ireland
From €1370EUR$1,500USD£1,172GBP
- Report
- December 2021
- 40 Pages
Germany
From €1370EUR$1,500USD£1,172GBP
- Report
- December 2021
- 40 Pages
France
From €1370EUR$1,500USD£1,172GBP
- Report
- December 2021
- 40 Pages
China
From €1370EUR$1,500USD£1,172GBP
- Report
- December 2021
- 40 Pages
Brazil
From €1370EUR$1,500USD£1,172GBP
- Book
- March 2024
- 528 Pages
- Book
- August 2012
- 552 Pages
The Oral Vaccine market is a subset of the larger Vaccines market, which is focused on the development and distribution of vaccines to prevent and treat infectious diseases. Oral Vaccines are administered orally, rather than through injection, and are typically used to protect against gastrointestinal infections. These vaccines are often used in developing countries, where access to injection-based vaccines may be limited. Oral Vaccines are also used in certain circumstances where injection-based vaccines may not be suitable, such as in the elderly or immunocompromised individuals.
Oral Vaccines are typically composed of weakened or killed pathogens, which stimulate the body’s immune system to produce antibodies against the disease. These vaccines are typically administered in multiple doses, and may require booster shots to maintain immunity.
Some companies in the Oral Vaccine market include GlaxoSmithKline, Merck, Sanofi, Pfizer, and Johnson & Johnson. Show Less Read more